The TransMet trial is a multicenter,prospective,randomized controlled study aimed at comparing the efficacy of liver transplantation combined with chemotherapy(LT+CT)versus chemotherapy(CT)alone in patients with unres...The TransMet trial is a multicenter,prospective,randomized controlled study aimed at comparing the efficacy of liver transplantation combined with chemotherapy(LT+CT)versus chemotherapy(CT)alone in patients with unresectable colorectal liver metastases(CRLM)(1).Patient enrollment took place between February 2016 and July 2021.This study enrolled patients aged 18 to 65 years with liver-confined metastases who demonstrated either a partial response or disease stabilization after at least 3 months of CT.The primary objective of the study was to assess 5-year overall survival(OS),with secondary outcomes including 3-year OS,3-and 5-year progression-free survival(PFS),as well as recurrence rates.展开更多
文摘The TransMet trial is a multicenter,prospective,randomized controlled study aimed at comparing the efficacy of liver transplantation combined with chemotherapy(LT+CT)versus chemotherapy(CT)alone in patients with unresectable colorectal liver metastases(CRLM)(1).Patient enrollment took place between February 2016 and July 2021.This study enrolled patients aged 18 to 65 years with liver-confined metastases who demonstrated either a partial response or disease stabilization after at least 3 months of CT.The primary objective of the study was to assess 5-year overall survival(OS),with secondary outcomes including 3-year OS,3-and 5-year progression-free survival(PFS),as well as recurrence rates.
